ArticleFrontiers in immunology2026
Shared Treg dysregulation underlies psoriasis vulgaris and atopic dermatitis through the PHF19-PRC2 epigenetic axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis vulgaris (PV) and atopic dermatitis (AD) are chronic inflammatory skin diseases characterized by distinct dominant T cell subsets, yet emerging evidence suggests overlapping immune mechanisms. Whether a shared Treg abnormality underlies both diseases remains unclear. Methods: Single-cell RNA sequencing data from lesional T cells of 8 PV, 7 AD, and 7 healthy controls were analyzed. Treg subset identification, trajectory, communication, and enrichment analyses were conducted. Differentially expressed genes from both diseases were intersected and subjected to Mendelian randomization to screen for shared causal genes, followed by interaction mapping, drug prediction, and molecular docking. Findings were validated in Foxp3-tdTomato reporter mouse models of imiquimod-induced psoriasis-like and MC903-induced AD-like dermatitis by flow cytometry and quantitative PCR. Results: A shared Treg triad remodeling pattern was identified: central memory Treg (cmTreg) was almost completely depleted, cycling Treg (Treg-c) expanded, and effector Treg (eTreg) accumulated in both diseases. Pseudotemporal analysis revealed a differentiation coordination defect, with upstream Treg-c shifting prematurely while effector Treg failed terminal maturation. Cell communication analysis identified enhanced MIF-(CD74+CXCR4/CD44) signaling as a shared intercellular remodeling axis, with the network shifting from a cmTreg-centric topology to one jointly centered on Treg-c and eTreg. Mendelian randomization identified seven shared causal genes (PDCD5, PHF19, GNAQ, LRR1, DHX36, TMEM107, FAM200B), with PHF19 serving as a core accessory subunit of PRC2. Molecular docking and Conclusions: Treg subset remodeling is a shared pathogenic feature, nominating PHF19-targeted activation as a tolerance-restoring therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.